NCT07336056Active, not recruitingPhase 4
Nerivio Efficacy Under High-Frequency Use
Safety Profile of High-Frequency Use of a Remote Electrical Neuromodulation (REN) Wearable Device for Migraine Treatment
Source: ClinicalTrials.gov · Last updated 13 Jan 2026
Brief summary (registry, in English)
This is a Post-marketing study investigating the impact of frequant usage with Nerivio on the safety profile of Remote Electrical Neuromodulation (REN) for the treatment of migraine. This study assessed the safety and tolerability of REN when used at frequencies exceeding the labeled indication.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 2000 (estimated)
- First submitted
- 9 Jan 2026
- Start date
- 8 Jan 2026
- Primary completion date
- 20 Jan 2026
- Lead sponsor
- Theranica
- Diseases
- Migraine
- NCT number
- NCT07336056
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 2000
- From 8 Jan 2026 to the primary completion date, 20 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Nerivio user
- Treated at least 4 times in a singe day, Or: treated at leastonce in 25 out of 28 consecutive days
- ExclusiveCriteria:
- None
Age in the registry: 8 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Theranica USA Inc Coordinator of this site? Confirm its status | Bridgewater | United States | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.